Ava Crowley Relapsed Neuroblastoma Expansion Trial
A Phase I/II Trial of DFMO in Combination With Bortezomib in Patients With Relapsed or Refractory Neuroblastoma
Dr. Sholler’s trial combines a first-in-children, investigational oral immunotherapy drug with chemotherapy to treat relapsed or progressive neuroblastoma. The Phase I trial treated 15 patients and CKc’s funding helped move the trial to Phase 2 as well as make it accessible to patients at 5 additional sites across the country, including CKc’s hometown of Orlando, Florida.
This Project By The Numbers
Years Active2 years
InstitutionHelen DeVos Children’s Hospital, Spectrum Health